Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar

Rocket Pharma (RCKT) announced an update on their ongoing clinical study.

The Phase 1 dose escalation trial “A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human Plakophilin-2a (PKP2a) Coding Sequence (RP-A601; AAVrh.74-PKP2a) in Subjects With Arrhythmogenic Cardiomyopathy Arising From Pathogenic PKP2 Variants (PKP2-ACM)” aims to test a one-time gene therapy in adults with a serious heart rhythm disorder. The goal is to gauge early safety and signs of benefit, which could support future larger trials and shape expectations for Rocket Pharmaceuticals’ long-term growth.

The treatment under study is RP-A601, a genetic therapy delivered by intravenous infusion. It is designed to carry a healthy PKP2 gene into heart cells to address the root cause of PKP2-related arrhythmogenic cardiomyopathy rather than just treating symptoms.

This is an interventional Phase 1 study that uses a sequential dose escalation design without randomization. All enrolled patients receive RP-A601, and there is no placebo or blinding, which is typical for early safety-focused research in rare and serious conditions.

Rocket Pharmaceuticals Inc. is running a single experimental arm where patients get a single ascending dose of RP-A601 in two back-to-back dose groups. The main purpose is treatment, with a focus on identifying a safe dose range that can justify later phase trials and potential regulatory discussions.

The study was first submitted on May 22, 2023, marking the official entry of the program into the clinical database. This timing helps investors track how quickly Rocket is moving from preclinical work into human data.

The primary completion date will mark when key safety and early efficacy data from the main treatment period are collected. That readout often becomes a major catalyst for the stock, as it offers the first view of whether the therapy is doing what it is supposed to do in patients.

The estimated overall completion date will indicate when long-term follow-up data should be available, which is critical for gene therapies where durability and late safety signals matter. Investors should watch those dates for potential updates on cardiac function, arrhythmia burden, and hospitalizations.

The most recent update to the record was submitted on April 14, 2026, signaling that the trial status and details have been refreshed and that the program remains active. Regular updates can boost confidence that the company is executing to plan, even before topline data are available.

From a market standpoint, this update reinforces Rocket’s positioning in cardiac gene therapy, a space with high unmet need and limited direct competition. Positive progress here could support valuation by adding another de-risking step to the pipeline beyond its hematology and metabolic programs.

Investors should keep in mind that Phase 1 gene therapy trials are high risk, with small patient numbers and wide outcome ranges, so any safety issue or muted efficacy could pressure RCKT shares. Conversely, even modest early signals could lift sentiment given the lack of effective disease-modifying options and growing interest in cardiovascular gene therapies from larger players.

For now, the RP-A601 study in PKP2 arrhythmogenic cardiomyopathy is ongoing with the latest update recorded, and investors can find further details and status changes on the ClinicalTrials.gov portal.

To learn more about RCKT’s potential, visit the Rocket Pharma drug pipeline page.